Prevalence of therapeutic or disease-relevant oncogenic alterations: An analysis of the AACR Project GENIE Biopharma Cooperative bladder cancer cohort
The prevalence of gene alterations is consistent with ranges reported in the literature. This analysis provides insights into the distribution of therapeutic or disease-relevant genetic biomarkers in patients with bladder cancer and helps the understanding of patient biomarker profile to support clinical development for patients with bladder cancer.
Authors
- Julia F. Markensohn
- Mehmet Burcu (ORCID: https://orcid.org/0000-0003-4572-0987)
- Xinyue Liu (ORCID: https://orcid.org/0000-0002-0934-4155)
- Răzvan Cristescu (ORCID: https://orcid.org/0000-0002-9978-0339)
- Cai Chen (ORCID: https://orcid.org/0000-0001-5606-1871)
- Jin‐Liern Hong (ORCID: https://orcid.org/0000-0001-9483-6316)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Publication Details
- Journal
- Urologic Oncology Seminars and Original Investigations
- Published
- 2025-10-16
- DOI
- https://doi.org/10.1016/j.urolonc.2025.08.031
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00